​

Palvella Therapeutics (PVLA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

PVLA Stock Forecast

Palvella Therapeutics (PVLA) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $203.92, with a high of $255.00 and a low of $143.00. This represents a 55.06% increase from the last price of $131.51.

PVLA Stock Rating

Palvella Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 1 Strong Buy (10.00%), 9 Buy (90.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 9 1 Strong Sell Sell Hold Buy Strong Buy

PVLA Price Target Upside V Benchmarks

TypeNameUpside
StockPalvella Therapeutics55.06%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts41630
Avg Price Target$231.25$199.56$154.40
Last Closing Price$131.51$131.51$131.51
Upside/Downside75.84%51.75%17.41%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-15---15
Feb, 26-15---15
Jan, 26-14---14
Dec, 25-12---12
Nov, 25310---13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 24, 2026Truist Financial$210.00$120.4174.40%59.68%
Feb 24, 2026Chardan Capital$210.00$118.6177.05%59.68%
Feb 24, 2026Stifel Nicolaus$250.00$119.26109.63%90.10%
Feb 24, 2026H.C. Wainwright$255.00$116.66118.58%93.90%
Jan 07, 2026Mizuho Securities$205.00$90.43126.69%55.88%
Dec 16, 2025Whitney IjemCanaccord Genuity$204.00$88.42130.72%55.12%
Dec 16, 2025Ryan DeschnerRaymond James$193.00$91.51110.91%46.76%
Dec 15, 2025Chardan Capital$174.00$88.4296.79%32.31%
Dec 15, 2025Jeff MukherjeeBTIG$192.00$88.42117.15%46.00%
Dec 15, 2025Truist Financial$190.00$88.89113.75%44.48%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 24, 2026H.C. WainwrightBuyBuyhold
Feb 02, 2026Cowen & Co.BuyBuyhold
Dec 16, 2025Cowen & Co.BuyBuyhold
Dec 16, 2025Raymond JamesStrong BuyStrong Buyhold
Dec 15, 2025BTIGBuyBuyhold
Dec 15, 2025UBSBuyBuyhold
Dec 15, 2025Cantor FitzgeraldOverweightOverweighthold
Dec 15, 2025OppenheimerOutperformOutperformhold
Dec 11, 2025H.C. WainwrightBuyBuyhold
Dec 05, 2025BTIGBuyinitialise

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-7.83---
Avg Forecast$-3.70$-2.77$-5.41$-2.81
High Forecast$-3.02$-1.60$-1.48$-1.37
Low Forecast$-4.37$-3.93$-12.67$-4.16
Surprise %111.62%---

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported----
Avg Forecast$50.00K--$5.62M
High Forecast$50.00K--$5.62M
Low Forecast$50.00K--$5.62M
Surprise %----

Net Income Forecast

$-30M $-24M $-18M $-12M $-6M $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-17.43M---
Avg Forecast$-8.22M$-6.15M$-15.75M$-6.15M
High Forecast$-6.72M$-3.56M$-3.29M$-3.05M
Low Forecast$-9.73M$-8.75M$-28.20M$-9.26M
Surprise %111.97%---

PVLA Forecast FAQ

Is Palvella Therapeutics stock a buy?

Palvella Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 9 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Palvella Therapeutics is a favorable investment for most analysts.

What is Palvella Therapeutics's price target?

Palvella Therapeutics's price target, set by 10 Wall Street analysts, averages $203.92 over the next 12 months. The price target range spans from $143 at the low end to $255 at the high end, suggesting a potential 55.06% change from the previous closing price of $131.51.

How does Palvella Therapeutics stock forecast compare to its benchmarks?

Palvella Therapeutics's stock forecast shows a 55.06% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Palvella Therapeutics over the past three months?

  • March 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Palvella Therapeutics’s EPS forecast?

Palvella Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.77, marking a -64.62% decrease from the reported $-7.83 in 2024. Estimates for the following years are $-5.41 in 2026, and $-2.81 in 2027.

What is Palvella Therapeutics’s revenue forecast?

Palvella Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, and $5.62M for 2027.

What is Palvella Therapeutics’s net income forecast?

Palvella Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-6.155M, representing a -64.70% decrease from the reported $-17.434M in 2024. Projections indicate $-15.748M in 2026, and $-6.155M in 2027.